Objective To observe the efficacy of the combined treatment of Reduning,budesonide and erythromycin sequential therapy in the treatment of children with mycoplasma pneumonia and investigate its mechanism.Methods 78 children with mycoplasma pneumonia were randomly divided into two groups,each group 39 cases.The control group were given budesonide and erythromycin sequential therapy,and the observation group were given Reduning injection on the basis of the control group.Both groups were treated for 2 weeks.The clinical efficacy was observed,and before and after treatment,the pulmonary function was tested in the both groups.Results The total effective rate of the observation group was 94.87％,which was higher than that of the control group(86.62％)(x2=6.683,P＜0.05);The fever,cough improved,pulmonary rales disappeared,wheeze disappeared and hospital stay time of the observation group were significantly shorter than the control group(all P＜0.01);The FVC,FEV1 and PEF of the observation group were higher than those of the control group(all P＜0.05).Conclusion On the basis of the combined treatment of budesonide and erythromycin,the addition of Reduning injection can improve clinical effect and shorten the symptoms and signs improve time,improve lung function,chich may in association with regulating humoral immunity and reducing the levels of inflammatory cytokines.

Object To study the pharmacokinetics of safflower yellow A, a major ingredient in the crude drug of Carthamus tinctorius L., in rats in vivo. Methods RP HPLC method was set up used to determine the content of safflower yellow A in plasma of rat. The chromatographic condition included Hypersil ODS2 column (200 mm?4.6 mm, 5 ?m); the mobile phase consisting of methanol 0.2% acetic acid (24∶76); the flow rate at 0.8 mL/min; the detective wavelength at 410 nm. Riboflavin was used as internal standard. Safflower yellow A was injected into the rats through caudal vein, and its concentrations at different time were determined in healthy rat after 24 h fasting. The data were processed with the software 3P87. Results The primary pharmacokinetic parameters were: V c (0 30?0 04) L/kg, CL (1.12?0.33) mL/min, K e (0.91?0.19) h -1 , t 1/2 (0 76?0 10) h, AUC (24.97?4.83) (?g?h)/mL, respectively in iv safflower yellow A to the rats. Conclusion The safflower yellow A in rats is fited to one compartment model, and it is distributed and eliminated quickly.

OBJECTIVETo construct self-assembly fibrocartilage model of goat temporomandibular joint disc and observe the biological characteristics of the self-assembled fibrocartilage constructs, further to provide a basis for tissue engineering of the temporomandibular joint disc and other fibrocartilage.

METHODSCells from temporomandibular joint discs of goats were harvested and cultured. 5.5 x 10(6) cells were seeded in each agarose well with diameter 5 mm x depth 10 mm, daily replace of medium, cultured for 2 weeks.

RESULTSOne day after seeding, goat temporomandibular joint disc cells in agarose wells were gathered and began to self-assemble into a disc-shaped base, then gradually turned into a round shape. When cultured for 2 weeks, hematoxylin-eosin staining was conducted and observed that cells were round and wrapped around by the matrix. Positive Safranin-O/fast green staining for glycosaminoglycans was observed throughout the entire constructs, and picro-sirius red staining was examined and distribution of numerous type I collagen was found. Immunohistochemistry staining demonstrated brown yellow particles in cytoplasm and around extracellular matrix, which showed self-assembly construct can produce type I collagen as native temporomandibular joint disc tissue.

CONCLUSIONProduction of extracellular matrix in self-assembly construct as native temporomandibular joint disc tissue indicates that the use of agarose wells to construct engineered temporomandibular joint disc will be possible and practicable.

HSP90, which is the biomarker of cell stress and endogenous protective protein, functions as a molecular chaperone. Many client proteins of HSP90, including EGFR, Met, Raf-1, IKK and p53, play important roles in the occurrence and development of tumor. Binding of HSP90 inhibitors triggers the deactivation of HSP90, resulting in client protein degradation, and hence inhibits the tumor growth by blocking multiple targets involved in signaling of tumor proliferation. This review summarizes recent development of small molecule inhibitors bound to N-terminal of HSP90.
Antineoplastic Agents ; chemistry ; HSP90 Heat-Shock Proteins ; antagonists & inhibitors ; Humans ; Neoplasms ; Signal Transduction

Limit test of flavones in diterpene ginkgolides meglumine injection materials by UV-Vis and HPLC-DAD method was studied in this essay. The HPLC-DAD method has lower LOD (about 1% of the UV-Vis), that is, the sensitivity is higher than UV-Vis method. Through the analysis of the kinds of flavonoids ingredients in the samples by LC-MS, the three compounds with highest contents are kaempferol, quercetin and isorhamnetin. Kaempferol, quercetin and isorhamnetin were chosen as reference compounds for HPLC analysis, and the HPLC separation analysis was carried on an Agilent Eclipse plus C18 column (4.6 mm x 250 mm, 5 μm) with methanol and water containing 0.4% phosphoric acid (50: 50) as mobile phase, and the flow rate was 1.0 mL x min(-1). The detection wavelength was set at 360 nm. This method has good specificity, precision and reproducibility. The LODs of quercetin, kaempferide and isorhamnetin were 27.6, 22.3, 29.5 μg x L(-1). The average recovery was 87.9% (RSD 3.3%), 91.7% (RSD 3.1%), 88.3 (RSD 1.3%) for quercetin, kaempferide and isorhamnetin, respectively. Based on the 10 batches of sample results and sensitivity of different HPLC, the content of total flavonoids ingredients of diterpene ginkgolides meglumine injection materials was limited no more than 2 x 10(-5). This method is simple, quick and has good maneuverability, and could be used to the limit test of flavonoids in the diterpene ginkgolides meglumine injection materials.
Chromatography, High Pressure Liquid ; methods ; Diterpenes ; analysis ; Drugs, Chinese Herbal ; analysis ; Flavones ; analysis ; Ginkgolides ; analysis ; Limit of Detection ; Mass Spectrometry ; methods

Objective:To analyze clinical characteristics of cutaneous delayed-type hypersensitivity caused by injection of equine tetanus antitoxin (TAT) or equine anti-tetanus immunoglobulin F (ab′) 2. Methods:Clinical data were collected from 181 outpatients or inpatients with cutaneous delayed-type hypersensitivity caused by injection of equine TAT or anti-tetanus immunoglobulin from 2008 to 2020, and retrospectively analyzed.Results:Before the injection of equine TAT or anti-tetanus immunoglobulin, skin test was negative in 171 (94.47%) of the 181 patients, and the 10 (5.53%) patients with positive skin test responses received desensitization injection. Among the 181 patients, there were 118 males and 63 females aged from 11 to 68 years, with the disease duration of 1 to 7 days and alatency period of 4 to 14 days. There was no significant difference in the clinical manifestations between the patients receiving injection of TAT (130 cases) and those receiving injection of equine anti-tetanus immunoglobulin (51 cases) . Urticaria-like rashes were the main clinical manifestation, and infiltrative erythema occurred at the injection site in 12 patients, of whom 10 developed generalized urticaria all over the body. Of the 181 patients, 163 (90.06%) presented with generalized skin rashes, and 56 (30.94%) had systemic symptoms such as chest tightness, fever, etc, of whom 15 (26.79%) had a history of allergies and 6 with severe symptoms had no history of allergies. Thirty-four (18.78%) patients had single or multiple laboratory abnormalities, such as increased white blood cell counts, elevated C-reactive protein level and urinary glucose, and presence of occult blood in urine. All cases responded well to the treatment with antihistamines and glucocorticoids. The treatment duration ranged from 3 to 10 days, and the outcome was good.Conclusion:TAT-or anti-tetanus immunoglobulin-induced cutaneous delayed-type hypersensitivity may still occur in patients with a negative skin test or after desensitization treatment, and mainly manifests as urticaria-like rashes.

AIM: In order to evaluate the applicable value of LDL as a targeted vehicle for chemotherapeutic agents, we investigated and compared the inhibitory effects of LDL-ACM complex and free ACM on nude mice's subcutaneous implanted tumors derived from gastric cancer cell lines, SGC-7901 and NKM-45. METHODS: LDL-ACM complex was prepared and the tumor model of nude mice was established by subcutaneous implantation of SGC-7901 and NKM-45. Then, the groups of nude mice developed subcutaneous implanted tumors were received either LDL-ACM complex or free ACM. Subsequently, the tumor size, weight and leukemia cell counts were measured and the rates of tumor-inhibition and the survival were compared among the groups. RESULTS: The inhibitory effects of LDL-ACM complex on the tumors, especially on SGC-7901 implanted tumors were much more obvious than that of free ACM. It was also indicated that the action of LDL-ACM complex was mediated by LDL receptor. CONCLUSION: These results showed that LDL-ACM complex had significant inhibitory effects on the implanted tumors and the effect might be mediated by LDL receptor.

Objective: To explore the relationship between blood levels of cyclophilin A (CyPA) and chronic heart failure (CHF).
Methods: A total of 166 CHF patients were enrolled as CHF group, according to NYHA classiifcation, it was further divided into 4 sub-groups: Class I,n=37, Class II,n=39, Class III,n=46 and Class IV,n=44. In addition, there was a Normal control group,n=52. Blood levels of CyPA, B-type natriuretic peptide (BNP) and high sensitivity C-reactive protein (hs-CRP) were examined and compared among different groups.
Results: Compared with Normal control group, CHF group had elevated CyPA (5.11 ± 2.43) ng/ml vs (2.28 ± 0.61) ng/ml, BNP (385.65 ± 184.06) pg/ml vs (90.37 ± 18.44) pg/ml and hs-CRP (11.74 ± 5.44) mg/L vs (5.99 ± 1.14) mg/L, all P<0.05. As increased severity of NYHA classiifcation, blood levels of CyPA, BNP and hs-CRP between 2 subgroups had the increasing trend accordingly, allP<0.05; while there was an exception: blood levels of CyPA and hs-CRP were similar between Class I subgroup and Normal control group, allP>0.05. Pearson correlation analysis indicated that blood levels of CyPA were positively related to BNP and hs-CRP in CHF patients (r=0.838,P<0.01 and r=0.755,P<0.01).
Conclusion: Blood levels of CyPA were elevated in CHF patients and it’s obviously related to NYHA classiifcation, which might have certain effects on CHF diagnosis and evaluation.

OBJECTIVE: To establish the method for content determination of 12 trace elements (Cu, Mn, Mg, Cd, Zn, Fe, Ba, Se, Pb, As, Cr, Ni) in Shiquan dabu pills, and to provide reference for further improvement of its quality control.METHODS: ICP-OES was adopted to detect. Microwave digestion was used for sample pretreatment with digestion power of 800 W; digestion process included heating to 120 ℃ keeping for 3 min, heating to 160 ℃ keeping for 5 min, and finally heating to 180 ℃ keeping for 20 min. PF power was 1 150 W, and pump speed was 50 r/min; the flow rate of atomizing gas was 0. 5 L/min, and that of plasma gas was 12. 0 L/min, detection wavelength of 182. 205-455. 403 nm. RESULTS: Results of 12 elements determination were all within standard range according to national standard substance sampling determination. The liner ranges of Cu, Mn, Mg, Cd, Zn, Fe, Ba, As, Cr and Ni were 0. 2-2. 0 mg/L, those of Se and Pb were 0. 4-4. 0 mg/L (r≥0. 999 5). The detection limits ranged 0. 1-8. 5 μg/L, and limits of quantitation were 0. 3-28. 3 μg/L. RSDs of precision tests were all lower than 1. 00％ (n=6). The average recovery rates were 88. 5％-99. 0％ (RSD were 1. 7％-4. 9％, n=6). CONCLUSIONS: The method is rapid, simple and sensitive, and it can be used for content determination of 12 trace elements in Shiquan dabu pills.

ngthen cellular immunity, especially Th1-type immune response to HPV11-E7 DNA vaccine in mice.